Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) EBT Margin (2016 - 2025)

Cytokinetics (CYTK) has disclosed EBT Margin for 16 consecutive years, with 269.98% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin changed N/A to 269.98% in Q4 2025 year-over-year; TTM through Dec 2025 was 434.87%, a N/A change, with the full-year FY2025 number at 747.21%, down 226958.0% from a year prior.
  • EBT Margin was 269.98% for Q4 2025 at Cytokinetics, up from 9856.3% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1122.4% in Q2 2024 to a low of 34233.07% in Q3 2023.
  • A 5-year average of 8233.46% and a median of 4582.31% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -2965076bps in 2023, then skyrocketed 1601213bps in 2024.
  • Cytokinetics' EBT Margin stood at 64.69% in 2021, then tumbled by -10492bps to 6851.66% in 2022, then fell by -17bps to 8049.16% in 2023, then crashed by -302bps to 32338.88% in 2024, then surged by 99bps to 269.98% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's EBT Margin are 269.98% (Q4 2025), 9856.3% (Q1 2025), and 32338.88% (Q3 2024).